{"url_path":"/sec/dftx/8-k/2026-05-12/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1813814/0001193125-26-218251-index.html","accession_number":"0001193125-26-218251","cik":"0001813814","ticker":"DFTX","issuer_name":"Definium Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1813814/0001193125-26-218251-index.html","primary_entity_key":"0001813814","primary_entity_name":"Definium Therapeutics, Inc."},"word_count":56,"has_tables":true,"body_markdown":"## Item 8.01 Other Events.\n\nOn May 12, 2026, Definium Therapeutics, Inc. (the “Company”) issued a press release announcing the first patient dosed in the Company's Phase 3 Ascend study of DT120 Orally Disintegrating Tablet in Major Depressive Disorder. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference herein."}